Rocío García Gómez

  • IBBTEC. C/ Albert Einstein, 22; 39011 Santander
  • garciagomezr@unican.es
  • 942 206 799 ext. 25907
  • Spatial Regulation of Ras-ERK Signals in Cancer
  • Cancer
  • Department of Cell & Molecular Signalling

​She received her first degree in Biotechnology from the University of León (Spain) in 2012. After a summer internship in 2010 at the laboratory of Dr. Piero Crespo, she got more interested in the biomedical research area; therefore, in 2013, she decided to study the Master's degree in molecular biology and Biomedicine at the University of Cantabria.

In 2014, Rocío joined IBBTEC, where she has been working in Spatial regulation of Ras-ERK signals in cancer group. After some years working under the supervision of Dr. Piero Crespo, last year she decided to enter the Molecular Biology and Biomedicine doctorate program at the University of Cantabria.

​Spatial Regulation of Ras-ERK Signals in Cancer


Research lines 

    • Spatial regulation of Ras-ERK signals in physiological processes and in cancer
    • Development of antitumoral drugs targeting protein-protein interactions in the Ras-ERK pathway


Funding

    • “Nuevas dianas moleculares en la ruta Ras-ERK: potencial terapéutico en el cáncer de tiroides”. Asociación Española Contra el Cáncer (AECC). GCB141423113. Proyecto coordinado 2014-2019. 
    • Red Temática de Investigación Cooperativa sobre el Cáncer (RTICC). RD/12/0036/0033. 2012-2015.
    • “Proteínas Scaffold como moduladores de la resistencia a inhibidores de la ruta RAS-ERK en melanoma”.  SAF-2015 63638R.  2016-2018.
    • Grupo incluido en: Centro de Investigación Biomédica en Red sobre el Cáncer (CIBERONC). (CB16/12/00436). 2017-2023.
    • “ERK spatial distribution and dimerization: implications in carcinogenesis”. RTI2018-096658B. 2019-2021.
    • “Repurposing MAPK inhibitors for the treatment of COVID-19”. Proyecto intramural CSIC. CSIC-COV19-095. 2020.
    • Grupo incluido en la Plataforma PTI SALUD GLOBAL-CSIC: SG2103031_2107300020.
    • “Reutilización de inhibidores de MAPK para el tratamiento de COVID-19”. G.CANTABRIA: 2020UIC22-PUB0008.
    • “Proteínas HOX como mediadores de la ruta RAS-ERK”. PID2021-126288OB-I00. 2022-2025. 294.000€. Investigador Principal.
    • “Desarrollo de un marcador de la respuesta terapéutica del melanoma BRAF positivo”. Proyectos de Prueba de Concepto PDC2022-133569-I00. 2023-2025.



Piero Crespo Baraja (IP)

View more

Lorena Agudo Ibáñez

View more

Ana Herrero Mier

View more

Daniel Molina Carreño

View more

Marta Morante Ezquerra

View more

Laura Ruiz Peinado

View more